Drugs / Vatelizumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02306811 | Feb 2015 → Apr 2016 | relapsing-remitting multiple sclerosis | Genzyme, a Sanofi Company | Terminated | No outcome recorded |
| Phase 2 | NCT02222948 | Sep 2014 → Apr 2016 | relapsing-remitting multiple sclerosis | Genzyme, a Sanofi Company | Terminated | No outcome recorded |
| Phase 2 | NCT01861249 | Jul 2013 → May 2014 | ulcerative colitis | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01659138 | Aug 2012 → Jun 2014 | ulcerative colitis | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vatelizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02306811 ↗ |
| Known as | GBR 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743086 ↗ |
| Known as | SAR339658 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01861249 ↗ |
| Action | Inhibit | “Integrin alpha-2 antagonist” CHEMBL1743086 ↗ |
| Modality | Monoclonal antibody | — CHEMBL1743086 ↗ |
| Route | Intravenous | “Route of administration: intravenous” NCT01659138 ↗ |
| Target | ITGA2 | “Integrin alpha-2 antagonist” CHEMBL1743086 ↗ |